Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Roundup: Optimer, Sopherion, Proteon, Pearl

This article was originally published in The Pink Sheet Daily

Executive Summary

Recent alternative financings include direct offerings to institutional investors, a private biotech out-licensing its lead compound to a holding company, and the latest equity/option deal for Novartis’ corporate venture with MPM Capital.

You may also be interested in...

Regulus Is On The Launch “Platform” With $20M Series A Financing

Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.

Optimer Rides High After OPT-80 C. Diff Trial Success

Phase III data show antibiotic non-inferior to Vancocin; additional trial results due mid-2009 with an NDA filing by year’s end.

MPM/Novartis Fund Deals with Radius

In mid-September, the MPM Capital/Novartis investment fund closed a $10 million investment in Radius Health -- getting an option on Radius's Phase II osteoporosis candidate and the first evidence that its strategy of melding business development with VC can work. And that's why the outcome will be important to watch. If the Radius deal is followed by others, Big Pharma will try to copy the model. If the deal is seen as preventing Radius from getting a profitable exit for its investors, serving Novartis' needs at their expense, corporate VC will go back to the drawing board.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts